- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03008109
Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC
January 2, 2017 updated by: Zaiwen Fan
Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer
EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS (progression-free survival) , the OS ( overall survival) is limited extended.
This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zaiwen Fan, MD
- Phone Number: +86 18610949919
- Email: kzzaiwenfan@163.com
Study Contact Backup
- Name: Zhaoyuan Shi, Bachelor
- Phone Number: +86 15801570739
- Email: szy957@aliyun.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced NSCLC,EGFR mutation positive,PS(performance status) 0-2,Patients were required to have one or more measurable lesions
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EGFR-TK inhibitor plus RH-endostatin
EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
progression-free survival
Time Frame: 18 month
|
18 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2017
Primary Completion (Anticipated)
November 1, 2017
Study Completion (Anticipated)
November 1, 2018
Study Registration Dates
First Submitted
December 29, 2016
First Submitted That Met QC Criteria
December 29, 2016
First Posted (Estimate)
January 2, 2017
Study Record Updates
Last Update Posted (Estimate)
January 4, 2017
Last Update Submitted That Met QC Criteria
January 2, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostatins
Other Study ID Numbers
- AirFGH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Bristol-Myers SquibbRecruitingAdvanced CancerUnited States, Spain, Belgium, Argentina, Korea, Republic of, Japan
Clinical Trials on EGFR-TK Inhibitor
-
Fudan UniversityRecruitingNon-small Cell Lung Cancer | Brain MetastasesChina
-
Qingdao Central HospitalRecruiting
-
LuBingUnknownCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung CancerChina
-
Xinqiao Hospital of ChongqingUnknownNon Small Cell Lung CancerChina
-
Zhejiang UniversityUnknownNon Small Cell Lung CancerChina
-
Abbisko Therapeutics Co, LtdRecruitingNon-Small Cell Lung CancerChina, United States
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Cancer Institute and Hospital, Chinese Academy...UnknownNon Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
-
Shanghai Pulmonary Hospital, Shanghai, ChinaUnknownNonsmall Cell Lung Cancer | EGFR Gene Mutation